Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 14-19 , January 2004

Logistics of radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin)

  • A.Michael Zimmer

      Affiliations

    • Department of Nuclear Medicine, Northwestern Memorial Hospital, Chicago, IL, USA
    • *Address reprint requests to A. Michael Zimmer, PhD, Nuclear Medicine Department, Northwestern Memorial Hospital, Galter Pavilion, 8th Floor, 251 E Huron, Chicago, IL 60611, USA
    • 1Dr Zimmer has received honoraria from Biogen Idec, Inc.

References 

  1. Wagner HN, Wiseman GA, Marcus CS, et al.  Administration guidelines for radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267–272
  2. Zevalin (ibritumomab tiuxetan) prescribing information. IDEC Pharmaceuticals Corporation, San Diego, CA; 2002;
  3. Knox SJ, Goris ML, Trisler K, et al.  Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457–470
  4. Wiseman GA, White CA, Stabin M, et al.  Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med. 2000;27:766–777
  5. Wiseman GA, White CA, Sparks RB, et al.  Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol. 2001;39:181–194
  6. Wiseman GA, Leigh B, Erwin WD, et al.  Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer. 2002;94:1349–1357
  7. Colcher D. Centralized radiolabeling of antibodies for radioimmunotherapy. J Nucl Med. 1998;39:11S–13S
  8. Siegel JA, Zimmerman BE, Kodimer K, et al.  A single dose calibrator dial setting accurately measures 90Y ibritumomab tiuxetan activity. J Nucl Med. 2003;44:317P
  9. Wiseman G, Leigh B, Witzig T, et al.  Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma. Eur J Nucl Med. 2001;28:1198; (abstr)
  10. Zimmer AM, Carey AM, Spies SM. Effectiveness of specific vial and syringe shields in reducing radiation exposure from Y-90 Zevalin. J Nucl Med. 2002;43:45P
  11. Zanzonico PB, Binkert BL, Goldsmith SJ. Bremsstrahlung radiation exposure from pure beta-ray emitters. J Nucl Med. 1999;40:1024–1028

PII: S0001-2998(03)00078-3

doi: 10.1053/j.semnuclmed.2003.11.001

Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 14-19 , January 2004

Article Tools

* Image Usage & Resolution